Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > The smart ones did not sell their shares..

<< Previous

Bullboard Posts

Next >>

Comment by Oenophileon Oct 29, 2020 2:12pm

189 Views

Post# 31804615

RE:RE:RE:RE:RE:RE:RE:RE:The smart ones did not sell their shares..

Probably true, Scotty, though I can't see anyone brokering another financing for this company for R107. Bay street can't sell this to their clients. No chance Barda funds this with so many promising therapeutics/prophylaxes in pre-clinical development that haven't been funded. If Salzman thought he could get funding Radikal would have kept it for themselves. The fact acquisition wasn't contingent on Barda financing was a huge red flag. Development will cost millions and take a years.

<< Previous

Bullboard Posts

Next >>

Gold vs. bitcoin, where should you invest?